JP2016504311A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504311A5
JP2016504311A5 JP2015546770A JP2015546770A JP2016504311A5 JP 2016504311 A5 JP2016504311 A5 JP 2016504311A5 JP 2015546770 A JP2015546770 A JP 2015546770A JP 2015546770 A JP2015546770 A JP 2015546770A JP 2016504311 A5 JP2016504311 A5 JP 2016504311A5
Authority
JP
Japan
Prior art keywords
agent according
cells
stro
progeny
endothelial dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015546770A
Other languages
English (en)
Japanese (ja)
Other versions
JP6572130B2 (ja
JP2016504311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/001452 external-priority patent/WO2014089623A1/en
Publication of JP2016504311A publication Critical patent/JP2016504311A/ja
Publication of JP2016504311A5 publication Critical patent/JP2016504311A5/ja
Application granted granted Critical
Publication of JP6572130B2 publication Critical patent/JP6572130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015546770A 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療 Active JP6572130B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
US61/736,361 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019123243A Division JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療

Publications (3)

Publication Number Publication Date
JP2016504311A JP2016504311A (ja) 2016-02-12
JP2016504311A5 true JP2016504311A5 (cg-RX-API-DMAC7.html) 2017-01-19
JP6572130B2 JP6572130B2 (ja) 2019-09-04

Family

ID=50933585

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015546770A Active JP6572130B2 (ja) 2012-12-12 2013-12-12 内皮機能不全及び炎症の疾患の治療
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019123243A Active JP6829288B2 (ja) 2012-12-12 2019-07-01 内皮機能不全及び炎症の疾患の治療
JP2021008250A Active JP7201715B2 (ja) 2012-12-12 2021-01-21 内皮機能不全及び炎症の疾患の治療
JP2022206042A Pending JP2023030116A (ja) 2012-12-12 2022-12-22 内皮機能不全及び炎症の疾患の治療
JP2024111736A Pending JP2024147655A (ja) 2012-12-12 2024-07-11 内皮機能不全及び炎症の疾患の治療

Country Status (11)

Country Link
US (2) US20160175360A1 (cg-RX-API-DMAC7.html)
EP (2) EP2931876B1 (cg-RX-API-DMAC7.html)
JP (5) JP6572130B2 (cg-RX-API-DMAC7.html)
KR (3) KR102217962B1 (cg-RX-API-DMAC7.html)
CN (2) CN111840329B (cg-RX-API-DMAC7.html)
AU (4) AU2013360024B2 (cg-RX-API-DMAC7.html)
CA (1) CA2893942C (cg-RX-API-DMAC7.html)
ES (1) ES2742035T3 (cg-RX-API-DMAC7.html)
IL (1) IL239308A0 (cg-RX-API-DMAC7.html)
SG (2) SG10201705061RA (cg-RX-API-DMAC7.html)
WO (1) WO2014089623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939417B (zh) 2007-12-04 2014-02-05 蛋白生物动力私人有限公司 祖细胞的保护和它们的分化的调节
ES2742035T3 (es) * 2012-12-12 2020-02-12 Mesoblast Inc Tratamiento de las enfermedades de la disfunción y la inflamación endotelial
JPWO2022114111A1 (cg-RX-API-DMAC7.html) * 2020-11-27 2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
PT1493439E (pt) * 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CN102391981B (zh) 2004-09-24 2014-08-20 麦索布莱斯特公司 多能扩增间充质前体细胞子代(memp)及其应用
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2006121445A2 (en) * 2005-05-10 2006-11-16 United States Of America Department Of Veteran's Affairs Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
CA2743682A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
CA2743698A1 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
CN101939417B (zh) * 2007-12-04 2014-02-05 蛋白生物动力私人有限公司 祖细胞的保护和它们的分化的调节
CN102076844B (zh) * 2008-06-30 2013-08-07 成血管细胞系统公司 采用组合疗法的眼病和过度血管新生的治疗
CN104546912B (zh) * 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
US20120195969A1 (en) * 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CA2837895C (en) * 2011-06-03 2021-07-27 Mesoblast, Inc. Methods of treating or preventing neurological diseases
ES3013463T3 (en) * 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
CA2880808C (en) * 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
ES2742035T3 (es) * 2012-12-12 2020-02-12 Mesoblast Inc Tratamiento de las enfermedades de la disfunción y la inflamación endotelial
ES2963968T3 (es) * 2013-01-09 2024-04-03 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas

Similar Documents

Publication Publication Date Title
Sinha et al. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach
Moreno et al. Pathophysiology of the cardiac late Na current and its potential as a drug target
JP2013523152A5 (cg-RX-API-DMAC7.html)
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
JP2016517888A5 (cg-RX-API-DMAC7.html)
JP2014508138A5 (cg-RX-API-DMAC7.html)
JP2018505158A5 (cg-RX-API-DMAC7.html)
PH12018500261A1 (en) Azole benzene derivative
JP2009537554A5 (cg-RX-API-DMAC7.html)
JP2017526619A5 (cg-RX-API-DMAC7.html)
JP2016511753A5 (cg-RX-API-DMAC7.html)
JP2016504311A5 (cg-RX-API-DMAC7.html)
JP2016502980A5 (cg-RX-API-DMAC7.html)
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
JP2016503794A5 (ja) 疾患の治療のための医薬組成物
JP2014533256A5 (cg-RX-API-DMAC7.html)
PH12015502264A1 (en) Pyrazole derivative
JP2011527984A5 (cg-RX-API-DMAC7.html)
JP2018510917A5 (cg-RX-API-DMAC7.html)
You et al. Pathogenic and therapeutic roles of extracellular vesicles in sepsis
JP2014506563A5 (cg-RX-API-DMAC7.html)
WO2021057061A1 (en) Senolytic and antiinflammatory prodrugs and methods of use thereof
JP2018509479A5 (cg-RX-API-DMAC7.html)
CN104398525B (zh) 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用
RU2018110607A (ru) Фармацевтическая композиция для предотвращения и лечения заболеваний печени, содержащая в качестве активного ингредиента кромолин или его фармацевтически приемлемую соль